XTLB
Income statement / Annual
Last year (2023), XTL Biopharmaceuticals Ltd.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, XTL Biopharmaceuticals Ltd.'s net income was -$1.78 M.
See XTL Biopharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
-$459,000.00
|
$1.47 M
|
$28,000.00
|
$69,000.00
|
$52,000.00
|
$29,000.00
|
$23,000.00
|
-$6,000.00
|
$41,000.00
|
| Cost of Revenue |
$0.00 |
$1,000.00 |
$1,000.00 |
$1,000.00 |
$0.00 |
$0.00 |
$1,000.00 |
$3,000.00 |
$7,000.00 |
$17.00 |
| Gross Profit |
$0.00 |
-$460,000.00 |
$1.47 M |
$27,000.00 |
$69,000.00 |
$52,000.00 |
$28,000.00 |
$20,000.00 |
-$13,000.00 |
$40,983.00 |
| Gross Profit Ratio |
0 |
1 |
1 |
0.96 |
1 |
1 |
0.97 |
0.87 |
2.17 |
1 |
| Research and Development
Expenses |
$31,000.00
|
$30,000.00
|
$30,000.00
|
$38,000.00
|
$35,000.00
|
$38,000.00
|
$43,000.00
|
$443,000.00
|
$578,000.00
|
$278,000.00
|
| General & Administrative
Expenses |
$734,000.00
|
$850,000.00
|
$1.00 M
|
$910,000.00
|
$807,000.00
|
$755,000.00
|
$1.19 M
|
$1.26 M
|
$1.41 M
|
$1.72 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$734,000.00
|
$850,000.00
|
$1.00 M
|
$910,000.00
|
$807,000.00
|
$755,000.00
|
$1.19 M
|
$1.26 M
|
$1.41 M
|
$1.72 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$9,000.00 |
$8,000.00 |
$7,000.00 |
$25,000.00 |
| Operating Expenses |
$765,000.00 |
$880,000.00 |
$1.03 M |
$948,000.00 |
$842,000.00 |
$793,000.00 |
$1.25 M |
$1.71 M |
$2.00 M |
$2.02 M |
| Cost And Expenses |
$765,000.00 |
$880,000.00 |
$1.03 M |
$948,000.00 |
$842,000.00 |
$793,000.00 |
$1.25 M |
$1.71 M |
$2.00 M |
$2.02 M |
| Interest Income |
$36.00 |
$36,000.00 |
$8,000.00 |
$33,000.00 |
$93,000.00 |
$87,000.00 |
$16,000.00 |
$0.00 |
$0.00 |
$10,000.00 |
| Interest Expense |
$0.00 |
$468,000.00 |
$21,000.00 |
$16,999.00 |
$29,000.00 |
$80,000.00 |
$29,000.00 |
$16,000.00 |
$6,000.00 |
$35,000.00 |
| Depreciation &
Amortization |
$1,000.00
|
$1,000.00
|
$1,000.00
|
$1,000.00
|
$842,000.00
|
$1,000.00
|
$1,000.00
|
$3,000.00
|
$7,000.00
|
$53,000.00
|
| EBITDA |
-$764,000.00
|
-$879,000.00
|
-$1.03 M
|
-$947,000.00
|
$0.00
|
-$792,000.00
|
-$1.25 M
|
-$2.56 M
|
-$2.00 M
|
-$1.97 M
|
| EBITDA Ratio |
0 |
0.84 |
-1.7 |
-38.75 |
-3.88 |
-86.38 |
-57.69 |
-37.48 |
62.67 |
-44.8 |
| Operating Income Ratio
|
0
|
1.92
|
-0.7
|
-33.86
|
-12.2
|
-15.25
|
-42.97
|
-111.35
|
601.83
|
-49.32
|
| Total Other
Income/Expenses Net |
-$1.02 M
|
-$468,000.00
|
$1.47 M
|
-$2.01 M
|
-$505,000.00
|
$3.78 M
|
$465,000.00
|
$16,000.00
|
-$1.63 M
|
-$97,000.00
|
| Income Before Tax |
-$1.78 M |
-$1.35 M |
$435,000.00 |
-$782,000.00 |
-$1.35 M |
$2.99 M |
-$781,000.00 |
-$2.55 M |
-$3.62 M |
-$2.12 M |
| Income Before Tax Ratio
|
0
|
2.94
|
0.3
|
-27.93
|
-19.52
|
57.42
|
-26.93
|
-110.65
|
603.67
|
-51.68
|
| Income Tax Expense |
$0.00 |
$961,000.00 |
-$1.47 M |
-$166,000.00 |
-$69,000.00 |
-$7.64 M |
-$457,000.00 |
$832,000.00 |
$2.31 M |
$505,000.00 |
| Net Income |
-$1.78 M |
-$2.31 M |
$1.90 M |
-$616,000.00 |
-$1.28 M |
$2.99 M |
-$781,000.00 |
-$2.55 M |
-$4.31 M |
-$2.53 M |
| Net Income Ratio |
0 |
5.03 |
1.3 |
-22 |
-18.52 |
57.42 |
-26.93 |
-110.65 |
718.5 |
-61.63 |
| EPS |
-0.0033 |
-0.42 |
0.36 |
-0.12 |
-0.25 |
0.58 |
-0.17 |
-0.93 |
-1.63 |
-1.09 |
| EPS Diluted |
-0.0033 |
-0.42 |
0.31 |
-0.12 |
-0.25 |
0.58 |
-0.17 |
-0.93 |
-1.63 |
-1.09 |
| Weighted Average Shares
Out |
$544.95 M
|
$5.45 M
|
$5.32 M
|
$5.14 M
|
$5.14 M
|
$5.14 M
|
$4.70 M
|
$2.74 M
|
$2.64 M
|
$2.31 M
|
| Weighted Average Shares
Out Diluted |
$544.91 M
|
$5.45 M
|
$6.16 M
|
$5.14 M
|
$5.14 M
|
$5.14 M
|
$4.70 M
|
$2.74 M
|
$2.64 M
|
$2.31 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
